Showing 1 - 20 results of 34,186 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ((( _ web decrease ) OR ( 42 we decrease ))))*', query time: 1.00s Refine Results
  1. 1

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…By all-atom simulation and molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) method, we have demonstrated that this compound strongly binds to both amyloid β42 (Aβ<sub>42</sub>) fibrils and β-secretase, and the van der Waals interaction dominates over the electrostatic interaction in binding affinity. …”
  2. 2

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…By all-atom simulation and molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) method, we have demonstrated that this compound strongly binds to both amyloid β42 (Aβ<sub>42</sub>) fibrils and β-secretase, and the van der Waals interaction dominates over the electrostatic interaction in binding affinity. …”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Network and biological properties of high quality marine food webs, ordered by decreasing connectance. by Tomás Ignacio Marina (5309588)

    Published 2018
    “…<p>Network and biological properties of high quality marine food webs, ordered by decreasing connectance.</p>…”
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  17. 17

    Decreased Risk of Ventilator-Associated Pneumonia in Sepsis Due to Intra-Abdominal Infection by François Philippart (319324)

    Published 2015
    “…The IAI group had fewer patients with VAP (56 [19.3%] <i>vs</i>. 806 [34.5%], <i>P</i><0.01) and longer time to VAP (5.0 <i>vs</i>.10.5 days; <i>P</i><0.01). After adjustment on independent risk factors for VAP and previous antimicrobial use, IAI was associated with a decreased risk of VAP (hazard ratio, 0.62; 95% confidence interval, 0.46–0.83; <i>P</i><0.0017). …”
  18. 18
  19. 19
  20. 20